

RESEARCH

Open Access



Short-term effect of ligature-induced periodontitis on cardiovascular variability and inflammatory response in spontaneously hypertensive rats

Aline Barbosa Ribeiro, Thais Marques da Silva, Nilton Nascimento Santos-Júnior, Jaci Airton Castania, Rubens Fazan Jr. and Helio Cesar Salgado*

Abstract

Background: We previously reported that periodontal disease (PD) induces high arterial pressure variability (APV) consistent with sympathetic overactivity and elicits myocardial inflammation in Balb/c mice. However, it is unknown whether PD can change APV and heart rate variability (HRV) in spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats. This study aimed to evaluate the hemodynamic level, HRV, and APV associating with myocardial inflammation and plasma concentrations of oxide nitric (NO) in SHR and WKY rats with PD.

Methods: Three weeks after bilateral ligation of the first mandibular molar, or Sham operation, the rats received catheters into the femoral artery and had their arterial pressure (AP) recorded the following day. Subsequently, plasma, heart, and jaw were collected. The NO was quantified by the chemiluminescence method in plasma, and the myocardial IL-1 β concentrations were evaluated by ELISA. In the jaw was evaluated linear alveolar bone loss induced by PD.

Results: The linear alveolar bone loss in jaws of SHR with PD was higher than in all other groups. AP and heart rate were higher in SHR than in their WKY counterparts. SHR with PD showed lower AP than control SHR. HRV and APV were different between SHR and WKY rats; however, no differences in these parameters were found between the animals with PD and their control counterparts. Plasma NO and myocardial IL-1 β concentrations were higher in SHR with PD as compared to control WKY. A significant correlation was found between linear alveolar bone loss and plasma NO and myocardial IL-1 β concentrations.

Conclusion: Our results demonstrated that short-term PD lowered the AP in SHR, which might be due to the higher levels of plasma NO. Even though PD did not affect either HRV or APV, it did induce myocardial inflammation, which can determine cardiovascular dysfunction in long-term PD.

Keywords: Nitric oxide, Periodontitis, Myocardial inflammation, Heart rate variability, Arterial pressure variability

Background

Hypertension is a severe public health problem due to its high prevalence [1]. It is a multifactorial clinical condition characterized by high and sustained levels of blood pressure, a significant predictor of cardiovascular risk [2]. The mechanisms involved in the development of hypertension include a decrease in heart rate variability, increased

*Correspondence: hcsalgado@fmrp.usp.br
Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Avenida dos Bandeirantes, Ribeirão Preto, São Paulo 14049-900, Brazil



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

blood pressure variability, autonomic imbalance (sympathetic overactivity and deficit in cardiac parasympathetic modulation), endothelial dysfunction (reduction of nitric oxide release), oxidative stress and inflammation [3–5]. Even though relatively recent studies have shown the role of the immune system (innate and adaptive immunity) in the onset of arterial hypertension [6, 7], the mechanisms involved in this morbidity still deserve thorough investigation. The inflammation associated with increased blood pressure manifests, systemically, increasing concentrations of circulating inflammatory markers,

such as C-reactive protein, cytokines, chemokines, and soluble adhesion molecules [8, 9]. Therefore, arterial hypertension has been considered nowadays as an inflammatory disease [10].

Epidemiological studies have revealed that periodontitis affects over 50% of the worldwide population [11], and it is likewise a major public health problem [12]. Periodontitis is a chronic inflammatory disease caused by dysbiosis of the oral microbiome and exacerbation of pro-inflammatory cytokines, including interleukin (IL)-1 β and IL-6, and nitric oxide (NO) production, which might lead to tissue destruction [13–15]. Also, nod-like receptor family pyrin domain-containing protein-3 (NLRP3) complex inflammasome, also is increased in plasma and saliva in patients, which is associated of the progression of inflammatory and adaptive immune responses [16]. Recent studies have shown that the harmful effects of periodontitis are not restricted to the oral cavity, but can also affect the whole organism [17].

It is known that changes in arterial pressure variability (APV), as well as in heart rate variability (HRV), are predictors of morbimortality in cardiovascular diseases [18–20]. Moreover, a growing body of evidence has associated, epidemiologically, periodontal inflammation with cardiovascular diseases, such as arterial hypertension [21]. Our group recently demonstrated that periodontitis impacts the overall arterial pressure variability (APV) and cardiac performance, increases sympathetic activity and myocardial inflammation in Balb/c mice [22]. However, the effects of periodontitis in APV and HRV in hypertensive condition are not yet well established.

The inflammatory response that accompanies periodontitis has been proposed as an essential factor that may affect coronary heart disease has been associated with galectin-3 levels, involving inflammatory signaling responses [23] and blood pressure regulation [24]. It has been postulated that this relationship could be either indirect, i.e., via similar risk factors [25], or direct, through the translocation of oral bacteria into the bloodstream, causing a generalized inflammatory response [26]. Moreover, studies have indicated that hypertension

accelerates the process of bone loss, which is intrinsically related to bone quality and density [27–30]. Periodontitis acting on the development and maintenance of arterial hypertension has been less consistently studied, especially regarding the hemodynamics, plasma NO levels, and inflammatory aspects.

Thus, the aim of this study was to evaluate the effect of periodontitis on HRV and APV. Moreover, to investigate, likewise, the mechanisms relating arterial hypertension and periodontitis, by evaluating the plasma levels of NO and IL-1 β concentration in the myocardial tissue.

Methods

Animals

All experiments were performed in twelve-weeks-old male Wistar Kyoto rats (WKY) and spontaneously hypertensive rats (SHR). The rats were purchased from the Institute of Biomedical Sciences (University of São Paulo) to ensure that the experimental animals used came from the desired strain. The animals were kept on a 12-h light–dark cycle with free access to food and water. All procedures adhered to the The Animal Research: Reporting in Vivo Experiments guidelines (ARRIVE) [31], and were approved by the Ethics Committee of Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil (protocol number 218/2019).

Experimental design

Under ketamine (50 mg/kg) and xylazine (10 mg/kg) anaesthesia, periodontitis was induced by ligation of the bilateral mandibular first molar with 4-0 sterile silk suture (Bioline, Anápolis, GO, Brazil). Control animals underwent to sham operation. After the surgery, animals received analgesic (Tramadol Hydrochloride, 12.5 mg/kg, subcutaneous). The rats were divided randomly into four groups: SHR with periodontal disease (n=5–7, SHR+PD); SHR without periodontal disease (n=5–7; SHR+Sham); WKY with periodontal disease (n=6–10, WKY+PD); and WKY rats without periodontal disease (n=6–7, WKY+Sham). Fourteen days after the initiation of periodontitis, a polyethylene catheter (Intramedic, Clay Adams, Parsippany, NJ) was implanted into the femoral artery for direct measurement of arterial pressure (AP) under ketamine (50 mg/kg) and xylazine (10 mg/kg) anaesthesia. At the following day, the arterial catheter was connected to a pressure transducer (MLT844; ADInstruments, Bella Vista, Australia) and the AP signal was amplified (ML224; ADInstruments, Bella Vista, Australia) and sampled by an IBM/PC attached to an analogue-to-digital interface (PowerLab, ADInstruments, Bella Vista, Australia). The experiments were conducted in conscious freely moving animals and AP was recorded continuously during 1 h. Following, rats were euthanised

with ketamine (150 mg/kg) and xylazine (30 mg/kg) anaesthesia, and blood, jaws, and heart were collected. The jaws were then fixed with 10% formalin, and the heart was immediately frozen in liquid nitrogen. Blood samples were centrifugation at 3500 rpm for 15 min at 4 °C. The plasma was then collected, and the heart was frozen at -80 °C and stored until analysis.

Evaluation of alveolar bone

The jaws were stained with 1% methylene blue (1 g/100 mL, diluted water) for 5 min after the remove soft tissues in 9% hypochlorite for 5 h. Following, the steps and procedures were performed as previously described [22]. Briefly, a digital camera coupled into a D.F. Vasconcellos microscope (Brazil) was used to the obtained images captured by StCamSWare 1.1. The measurement process was performed at three points on the buccal and lingual surfaces of first molar, calculating the distance (mm) between the cemento-enamel junction and alveolar bone crest. The mean values in pixels were converted into millimetres using the markings of the ruler to which the jaw was attached as a reference using Image J (National Institutes of Health, USA) computer software.

Direct pressure measurement data analysis

Pulsatile AP recordings were processed by a computer software (Blood Pressure Module for LabChart Pro, ADInstruments, Castle Hill, NSW, Australia), which employs algorithms to detect cycle-to-cycle inflection points in the pulsatile AP signal, to extract beat-by-beat time series of systolic AP and pulse interval (PI). Artefacts and ectopic beats were removed from the series if the values that exceeded 0.1- to 0.2-times the moving average of the signal. The excluded values did not exceed 1% of the overall series length [32, 33].

Heart rate and systolic AP variability

Overall, time domain, systolic AP variability was determined by the standard deviation of successive AP values (SD) while PI variability was quantified by the standard deviation of normal-to-normal intervals (SDNN), and also by the root mean square of successive PI differences (RMSSD). These parameters were calculated in a sliding window (no overlap) of 1500 beats.

The AP and PI variability were also studied in the frequency domain by spectral analysis. PI and systolic AP beat-by-beat time series were converted to evenly spaced series at 10 Hz using cubic spline interpolation and divided in 50% overlapped segments of 512 points. The spectrum of each segment was calculated using fast Fourier transform and integrated in low- (LF, 0.2–0.8 Hz) and high-frequency bands (HF, 0.8–3.0 Hz). The median

powers at LF and HF bands in absolute (abs) and normalized units (un), as well as the LF/HF ratio were estimated. Normalized values were obtained only for the PI series by calculating the proportion of LF and HF power relative to the total power of the spectrum.

Dynamic symbolic analysis, as proposed by Porta [34], was also evaluated for PI and systolic AP. The series of were converted in a sequence of symbols and evaluated in sets of three. The PI and systolic AP were uniform quantization, to the full range of values is divided into six equal levels. Each level is represented by a symbol (0 to 5), and all points within the same level were assigned the same symbol. After, sequences of three consecutive symbols were classified according to their variation pattern as zero (0 V), one (1 V), or two-unlike (2UV) variations. The data is presented in the percentage of patterns classified in each family.

Plasma NO levels measurement

NO measurement was performed indirectly by sodium nitrate quantification chemiluminescence according to a previous study [35]. Briefly, plasma (50 µL) was deproteinized using 100 µL of absolute ethanol at 4° C for 30 min. Then, the samples were centrifuged (10.000 rpm, 10 min, 25° C) and the supernatant was used to measure nitrate nitrite using a Sievers NO Analyzer (Sievers 280 NOA; Sievers, Boulder, CO). The sodium nitrate (Sigma-Aldrich Brazil, São Paulo, Brazil) was used as a standard reference.

IL-1β myocardial concentration measurement

Myocardial samples were homogenized in 0.5 mL of PBS and then centrifuged at 3500 rpm for 15 min at 4 °C. In the supernatants of samples were measured the IL-1β using appropriate ELISA kits (R&D Systems, Minneapolis, Minn., USA) according to the manufacturer's instructions. The total protein was measured by the Bradford method (Bio-Rad Laboratories).

Statistical analysis


Statistical analyses were performed using two-way analyses of variance (ANOVA), and significant differences were obtained using the Bonferroni's multiple comparisons post-hoc test, or Kruskal–Wallis—a nonparametric statistical test—followed by Dunn's post hoc test when the data did not pass the Shapiro–Wilk test of normality. Correlations were evaluated using Pearson correlation. Data are expressed as the mean ± standard error of the mean. For all analysis, statistical significance was considered when $P < 0.05$.

Results

Alveolar bone loss measurement

Figure 1 shows the impact of hypertension on bone alterations after PD, evaluated by three measurements

of the distance between the alveolar bone crest and cemento-enamel junction in the mean between buccal and lingual surfaces and right and left sides in the first molar.



In the right molar, WKY rats with PD and SHR rats with PD showed approximately 104% and 179%, respectively, higher linear bone alveolar loss than WKY without PD ($P < 0.05$). Moreover, SHR rats with PD showed 36% higher linear alveolar bone loss than WKY rats with PD ($P < 0.05$). On the other hand, no change in linear alveolar bone loss between SHR rats without PD and WKY rats without PD in both first molars.

As expected, SHR rats with PD showed approximately 163% and 28% higher distances from the cemento-enamel junction to the alveolar bone crest compared to either sham-operated counterparts and WKY rats with PD, respectively, in the left first molar ($P < 0.05$).

Hemodynamics and its variability

As expected, SHR presented higher values of mean arterial pressure (MAP) and HR (171 ± 3 mmHg and 308 ± 10 bpm) as compared to WKY rats (116 ± 5 mmHg and 317 ± 7 bpm). In WKY rats, the presence of PD did not elicit any change in either MAP (120 ± 5 mmHg) or HR (317 ± 7 bpm). On the other hand, MAP of SHR with PD was found lower (152 ± 2 mmHg) than its control counterparts. HR was similar between SHR with or without PD.

Table 1 shows variability indices of systolic AP and HR in the 4 groups of rats evaluated. Overall systolic AP variability (SD) and also the power of the LF oscillations of AP were higher in SHR as compared to WKY. However, PD did not elicit any change in systolic AP variability in either, SHR or WKY rats.

Table 1 Systolic arterial pressure and pulse interval indices of variability in time and frequency domains

	WKY Sham	WKY PD	SHR Sham	SHR PD
Systolic arterial pressure				
SD (mmHg)	4.8 ± 0.3	5.2 ± 0.2	8.8 ± 0.3*	6.6 ± 0.7*
LF (mmHg ²)	2.7 ± 0.8	2.7 ± 0.4	15.8 ± 0.7*	12.3 ± 1.5*
Pulse interval				
SDNN	7.9 ± 0.9	8.5 ± 0.6	7.9 ± 0.7	7.0 ± 1.0
RMSSD	5.8 ± 0.6	6.6 ± 0.4	4.9 ± 0.2*	4.9 ± 0.8*
LF (nu)	14.3 ± 1.4	16.5 ± 2.3	22.4 ± 2.0*	20.8 ± 1.7*
HF (ms ²)	7.3 ± 1.5	8.8 ± 0.9	6.3 ± 0.6	7.3 ± 2.3

Values (means ± SEM) of variability indices of systolic arterial pressure and pulse interval (PI) variability in time and frequency domain. SD: standard deviation of AP values; SDNN: SD of normal-to-normal values of PI; RMSSD: square root of the mean of the sum of the square of differences between successive values of pulse interval; LF and HF: power of AP or PI spectra at low- (0.2 to 0.8 Hz) and high-frequency (0.8 to 3 Hz), respectively; nu: normalized units. * $P < 0.05$ compared to sham operated WKY. # $P < 0.05$ compared to sham operated SHR. WKY: Wistar Kyoto rats without periodontal disease (WKY + Sham, n = 7); WKY: Wistar Kyoto rats with periodontal disease (WKY + PD, n = 10); SHR: Spontaneously hypertensive rats without periodontitis (SHR + Sham, n = 7); SHR: Spontaneously hypertensive rats with periodontitis (SHR + PD, n = 6)


SDNN was similar among the groups; however, RMSSD was lower and LF power of PI spectra was markedly higher in SHR as compared to normotensive WKY rats. Similarly to the findings with AP variability, PD also did not cause any change in HRV in both strains of rats evaluated in this study.


Symbolic analysis

The results of the symbolic analysis are shown in Fig. 2. 0 V pattern of systolic AP was similar among the four groups, but the percentage 1 V pattern, an index linked to sympathetic vascular modulation, was significantly higher in SHR than WKY with PD ($41 \pm 1\%$ and $35 \pm 1\%$). Nevertheless, the incidence of 0 V pattern of the IP, also an index of sympathetic cardiac modulation, was similar among all groups. The percentage of 2UV pattern of PI, a solid index of cardiac vagal modulation was found markedly lower in SHR as compared to WKY rats ($42 \pm 2\%$ and $59 \pm 3\%$). PD did not affect the incidence of 2UV pattern of HRV.

Plasma NO and IL-1β myocardial measurements

The plasma nitrate levels and the concentrations of IL-1β in the heart of the animals studied are presented in Fig. 3.





As one can see, PD elicited a marked increase in plasma nitrate levels in both strains of rats evaluated. However, PD increased cardiac IL-1 β concentrations in SHR only. This figure also shows the positive and significant relationship between mandibular bone loss and plasma nitrate or cardiac of IL-1 β .

Discussion

In the present study, the linear alveolar bone loss in jaws of SHR with PD was higher than in all other groups. AP and heart rate were higher in SHR than in their WKY counterparts. However, SHR with PD showed lower AP than SHR without PD. HRV and APV were different between SHR and WKY rats; however, no significant differences in these parameters were found between the animals with PD and their control counterparts. Also, a significant correlation was found between linear alveolar bone loss and plasma NO and myocardial IL-1 β concentrations, which were higher in SHR with PD than WKY without PD. Then, short-term (15 days) experimental PD presented a decrease in AP levels in SHR, which might be due to the higher levels of plasma NO. In addition, PD

induced myocardial inflammation, which can determine cardiovascular dysfunction in the future.

Ligature-induced PD is one of the most widely used experimental model in different animal species, including rats, mice, dogs and primates [36]. This model displays a body of outcomes similar to those exhibited by humans [37], i.e., local exacerbated pro-inflammatory response, junctional epithelium apical migration, and bone loss [38, 39]. Previous studies have proven that the harmful effects of ligature-induced PD are aggravated by arterial hypertension [27, 40]. The arterial hypertension enhances bone loss and impairs bone repair [27, 40]. In line with these studies, in the current study, PD increased alveolar bone loss in SHR. Nevertheless, the impact of PD in the hemodynamics (APV and HRV) of a hypertensive condition is poorly understood.

Previous studies showed that the impact of PD is not restricted to the oral cavity, but can be associated with systemic diseases, such as arterial hypertension, myocardial infarction, stroke, and atherosclerotic vascular disease [21, 25, 41, 42]. Moreover, our laboratory showed that 30 days of ligature-induced PD in mice decreased

the cardiac function (reduction of ejection fraction and cardiac output) and induced autonomic imbalance characterized by sympathetic overactivity [22]. Patterns of variability of cardiovascular parameters (HRV and APV) are well documented, and being widely used as predictors of morbidity and mortality in different cardiovascular and systemic diseases, at clinical and experimental conditions [23, 24]. However, to our knowledge, this is the first experimental study that evaluated the impact of PD on cardiovascular variability in hypertensive rats, particularly in the SHR.

In order to examine the effects of PD on a hypertensive condition, the SHR was chosen as the experimental model. SHR is one of the most widely-used genetic models of arterial hypertension, because it is considered the experimental model of human essential hypertension [43]. Apropos, the SHR show systemic manifestations similar to the human disorder, such as hemodynamic and endocrine outcomes [43]. Moreover, the normotensive control counterparts used in the current study were the WKY rats, because these animals have the same genetic background of the SHR, without exhibiting a spontaneous increase in arterial pressure [43]. In fact, in this study, the SHR showed, as expected, higher AP and HR levels when compared to their WKY counterparts. Moreover, the SHR also showed higher values of the overall APV, AP spectra at the low-frequency (LF) band, and incidence of 1 V sequences from the symbolic analysis. Also, the SHR showed low overall HRV, low indices of HRV linked to parasympathetic cardiac modulation (HF power of HR spectra and RMSSD), and high indices of HRV related to sympathetic activity (LF power of HR spectra). These results are in line with previous studies, which demonstrated sustained sympathetic overactivity, and decreased parasympathetic modulation in SHR, compared to WKY [44–48].

Nevertheless, the presence of PD did not affect the variability indices of HR and AP in neither WKY nor SHR. These findings may be related to the short-term development (15 days) of PD since our laboratory showed an impact of PD in APV indices only after 30 days of dental ligature in mice [22]. However, surprisingly, the SHR with PD showed a lower AP than their counterparts submitted to Sham surgery. Given that ligature-induced PD and SHR rats do not reproduce all aspects of human disease and the current study used a short time frame of investigation, the results must be cautiously interpreted and carefully extrapolated to a clinical context. Nevertheless, a possible mechanism for this finding might be associated with the higher plasma levels of NO-induced PD. NO is a short living product synthesized from L-arginine by a family of enzymes: Type 1-NO synthase-neuronal enzyme; Type 2-NO synthase-inducible enzymes (iNOS)

found in macrophages; and Type 3-NO synthase—endothelial cell enzymes (eNOS) [49]. NO is an endothelial-derived relaxant of the vascular smooth muscle and an inflammatory mediator, regulating vascular homeostasis [50]. The overproduction of NO by active macrophages induces nonspecific immunity and cytotoxic effect against invading microbial pathogens triggered by PD [49]. Moreover, the high levels of NO increase the damage of cellular proteins and lipids, leading to PD progression [49]. Previous studies also demonstrated that animals chronically treated with NO synthase inhibitors develop arterial hypertension, characterized by endothelial dysfunction [51, 52].

Recently, PD has also been associated with transient endothelial dysfunction [53–55] and increased levels of plasma NO [56]. Clinical and experimental studies have discussed the role of NO in the progression of PD. The increase of NO is not restricted to the oral cavity, but some studies showed that patients with periodontitis had increased plasma concentration of NO (nitrate and nitrite) [56, 57]. In fact, the results of the current study showed a significant increase of plasma NO levels, which were correlated with the development of local alveolar bone loss in PD and the short-term hypotensive response. This result is in line with the previous study that showed a role for NO associated with the severity of human periodontal disease [58]. Nevertheless, Menaka and co-workers revealed that individuals with PD had significantly higher NO levels in the serum than healthy subjects [56]. Moreover, Lohianai and co-workers showed that the augmented production of NO played a significant role in the pathogenesis of PD [59]. Besides, Herrera and co-workers demonstrated that NO contributes to the physiopathogenesis of PD since the concomitant bone loss is significantly reduced in L-NAME treated rats [60]. On the other hand, Higashi and co-workers showed that PD impairs endothelium-dependent vasodilation in both healthy and hypertensive young men, by decreasing NO availability [54]. Although the available information on NO production during PD is still controversial, the current study corroborates with the notion that there is an increase of NO release in response to PD. Thus, the NO overproduction observed in the present study would justify the hypotensive response in SHR.

New insights have been reported that galectin-3 and NLRP3 increase in PD patients and play a role in dysbiosis's inflammatory and immune response [16, 23]. Galectin-3 has been demonstrated to be implicated during the host defense against microbes, while NLRP3 induces up-regulation of IL-1 β , a proinflammatory cytokine-mediated by inflammasome activation [16, 23]. Moreover, IL-1 β increases tissue destruction, osteoclast formation, and bone resorption. These functions affect neutrophil

chemotaxis and activation, and endothelial cell function. In fact, chronic inflammation caused by PD is involved in systemic effects in distant organs, such as the heart [61–65]. In the current study the hearts from SHR with PD showed increased pro-inflammatory cytokine IL-1 β concentrations. Herrera and co-workers suggested that NO mediates the systemic effects of PD on myocardial tissue, which may be due to the transient bacteremia or the immunological activation caused by the dysbiosis of oral microorganisms in the ligature-induced PD rats [60]. The presence of IL-1 β is strongly associated with cardiovascular diseases, which could cause a long-term derangement of the heart and autonomic function; while its inhibition decreases AP, arterial hypertension and residual inflammatory risk [9, 66]. Thus, further studies are needed to elucidate the role of IL-1 β induced by long-term PD in the modulation of the autonomic nervous system and the AP response.

Conclusion

In conclusion, the current study's data support the notion that PD increases the NO levels in the blood, which could affect the AP in SHR. However, PD did not affect either HRV or APV. In addition, the observations of the present study strongly suggest that the inflammation induced by PD in first molars can lead to an increase in IL-1 β in myocardial tissue. Further studies should be conducted to evaluate the cardiovascular function in long-term experimental PD in SHR.

Abbreviations

PD: Periodontal disease; NO: Nitric oxide; AP: Arterial pressure; APV: Arterial pressure variability; NLRP3: Nod-like receptor family pyrin domain-containing protein-3; HRV: Heart rate variability; SHR: Spontaneously hypertensive rats; WKY: Wistar-Kyoto rats.

Acknowledgements

The authors thank the Dr. Evelin Capellari Cárnio (Nursing School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil) for NO measurement.

Authors' contributions

ABR contributed with the conception, data acquisition, analysis of the results, and participated in editing the manuscript. TMS contributed to the experiments, performed the analysis of the variabilities of heart rate and arterial pressure and revising the manuscript. NNS contributed to the experiments and ELISA analysis. JAC worked as a surgical technician. RF contributed with data analysis, revising it for intellectual content and writing the manuscript. HCS contributed with conception, supervision, and writing the manuscript. All authors read and approved the final manuscript.

Funding

This research was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) process #2020/06043-7, ABR holds a Postdoctoral (process #2018/10455-9) Scholarships from FAPESP and NNS holds a Postdoctoral (process #2018/20939-3) from FAPESP; and Conselho Nacional de Desenvolvimento Científico (CNPq) and Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto (FAEPA). They provided funding for purchasing materials and caring for experimental animals.

Availability of data and materials

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

All procedures adhered to the The Animal Research: Reporting in Vivo Experiments guidelines (ARRIVE) [28], and were approved by the Ethics Committee of Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil (protocol number 218/2019).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflicts of interests.

Received: 21 June 2021 Accepted: 30 September 2021

Published online: 11 October 2021

References

- Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. *J Hypertens*. 2018;36(12):2284–309. <https://doi.org/10.1097/HJH.0000000000001961>.
- Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. *JAMA Cardiol*. 2017;2(7):775–81. <https://doi.org/10.1001/jamacardio.2017.1421>.
- Pikkujämsä SM, Huikuri HV, Airaksinen KE, Rantala AO, Kauma H, Lilja M, et al. Heart rate variability and baroreflex sensitivity in hypertensive subjects with and without metabolic features of insulin resistance syndrome. *Am J Hypertens*. 1998;11(5):523–31. [https://doi.org/10.1016/S0895-7061\(98\)00035-1](https://doi.org/10.1016/S0895-7061(98)00035-1).
- Mancia G, Parati G, Castiglioni P, Tordi R, Tortorici E, Glavina F, et al. Daily life blood pressure changes are steeper in hypertensive than in normotensive subjects. *Hypertension*. 2003;42(3):277–82. <https://doi.org/10.1161/01.HYP.00000084632.33942.5F>.
- Incalza MA, D'Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. *Vascul Pharmacol*. 2018;100:1–19. <https://doi.org/10.1016/j.vph.2017.05.005>.
- Drummond GR, Vinh A, Guzik TJ, Sobey CG. Immune mechanisms of hypertension. *Nat Rev Immunol*. 2019;19(8):517–32. <https://doi.org/10.1038/s41577-019-0160-5>.
- Itani HA, McMaster WG, Saleh MA, Nazarewicz RR, Mikolajczyk TP, Kaszuba AM, et al. Activation of human T cells in hypertension: studies of humanized mice and hypertensive humans. *Hypertension*. 2016;68(1):123–32. <https://doi.org/10.1161/HYPERTENSIONAHA.116.07237>.
- Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. *J Exp Med*. 2007;204(10):2449–60. <https://doi.org/10.1084/jem.20070657>.
- Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, et al. Inflammation, immunity, and hypertension. *Hypertension*. 2011;57(2):132–40. <https://doi.org/10.1161/HYPERTENSIONAHA.110.163576>.
- Solak Y, Afsar B, Vaziri ND, Aslan G, Yalcin CE, Covic A, et al. Hypertension as an autoimmune and inflammatory disease. *Hypertens Res*. 2016;39(8):567–73. <https://doi.org/10.1038/hr.2016.35>.
- Kassebaum NJ, Bernabé E, Dahiya M, Bhandari B, Murray CJ, Marcenes W. Global burden of severe periodontitis in 1990–2010: a systematic review and meta-regression. *J Dent Res*. 2014;93(11):1045–53. <https://doi.org/10.1177/0022034514552491>.

12. Tonetti MS, Van Dyke TE, Joint EFPAAPW. Periodontitis and atherosclerotic cardiovascular disease: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases (Reprinted from Journal of Clinical Periodontology, vol 40, pg S24–S29, 2013). *J Periodontol*. 2013;84(4):S24–S9. <https://doi.org/10.1902/jop.2013.1340019>.
13. Darveau RP. Periodontitis: a polymicrobial disruption of host homeostasis. *Nat Rev Microbiol*. 2010;8(7):481–90. <https://doi.org/10.1038/nrmicr02337>.
14. Yucel-Lindberg T, Båge T. Inflammatory mediators in the pathogenesis of periodontitis. *Expert Rev Mol Med*. 2013;15:e7. <https://doi.org/10.1017/erm.2013.8>.
15. Isola G, Lo Giudice A, Polizzi A, Alibrandi A, Murabito P, Indelicato F. Identification of the different salivary Interleukin-6 profiles in patients with periodontitis: a cross-sectional study. *Arch Oral Biol*. 2021;122: 104997. <https://doi.org/10.1016/j.archoralbio.2020.104997>.
16. Isola G, Polizzi A, Santonocito S, Alibrandi A, Williams RC. Periodontitis activates the NLRP3 inflammasome in serum and saliva. *J Periodontol*. 2021. <https://doi.org/10.1002/JPER.21-0049>.
17. Nazir MA. Prevalence of periodontal disease, its association with systemic diseases and prevention. *Int J Health Sci (Qassim)*. 2017;11(2):72–80.
18. Schroeder EB, Liao D, Chambless LE, Prineas RJ, Evans GW, Heiss G. Hypertension, blood pressure, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. *Hypertension*. 2003;42(6):1106–11. <https://doi.org/10.1161/01.HYP.0000100444.71069.73>.
19. Virtanen R, Jula A, Kuusela T, Helenius H, Voipio-Pulkkinen LM. Reduced heart rate variability in hypertension: associations with lifestyle factors and plasma renin activity. *J Hum Hypertens*. 2003;17(3):171–9. <https://doi.org/10.1038/sj.jhh.1001529>.
20. Johansson M, Gao SA, Friberg P, Annerstedt M, Carlström J, Ivarsson T, et al. Baroreflex effectiveness index and baroreflex sensitivity predict all-cause mortality and sudden death in hypertensive patients with chronic renal failure. *J Hypertens*. 2007;25(1):163–8. <https://doi.org/10.1097/01.hjh.0000254377.18983.eb>.
21. Muñoz Aguilera E, Suvarn J, Buti J, Czesnikiewicz-Guzik M, Barbosa Ribeiro A, Orlandi M, et al. Periodontitis is associated with hypertension: a systematic review and meta-analysis. *Cardiovasc Res*. 2020;116(1):28–39. <https://doi.org/10.1093/cvr/cvz201>.
22. Ribeiro AB, Santos-Junior NN, Luiz JPM, de Oliveira M, Kanashiro A, Taira TM, et al. Cardiovascular and autonomic dysfunction in murine ligature-induced periodontitis. *Sci Rep*. 2020;10(1):6891. <https://doi.org/10.1038/s41598-020-63953-1>.
23. Isola G, Polizzi A, Alibrandi A, Williams RC, Lo GA. Analysis of galectin-3 levels as a source of coronary heart disease risk during periodontitis. *J Periodontol Res*. 2021;56(3):597–605. <https://doi.org/10.1111/jre.12860>.
24. Czesnikiewicz-Guzik M, Nosalski R, Mikołajczyk TP, Vidler F, Dohnal T, Dembowska E, et al. Th1-type immune responses to *Porphyromonas gingivalis* antigens exacerbate angiotensin II-dependent hypertension and vascular dysfunction. *Br J Pharmacol*. 2018.
25. Chistiakov DA, Orekhov AN, Bobryshev YV. Links between atherosclerotic and periodontal disease. *Exp Mol Pathol*. 2016;100(1):220–35. <https://doi.org/10.1016/j.yexmp.2016.01.006>.
26. Hujoel PP, Drangsholt M, Spiekerman C, DeRouen TA. Periodontal disease and coronary heart disease risk. *JAMA*. 2000;284(11):1406–10. <https://doi.org/10.1001/jama.284.11.1406>.
27. Bastos MF, Brillhante FV, Goncalves TED, Pires AG, Napimoga MH, Marques MR, et al. Hypertension may affect tooth-supporting alveolar bone quality: a study in rats. *J Periodontol*. 2010;81(7):1075–83. <https://doi.org/10.1902/jop.2010.090705>.
28. de Medeiros Vanderlei JM, Messori MR, Fernandes PG, Novaes AB, Palioti DB, de Moraes Grisi MF, et al. Arterial hypertension perpetuates alveolar bone loss. *Clin Exp Hypertens*. 2013;35(1):1–5. <https://doi.org/10.3109/10641963.2012.683969>.
29. Funaki S, Tokutomi F, Wada-Takahashi S, Yoshino F, Yoshida A, Maehata Y, et al. *Porphyromonas gingivalis* infection modifies oral microcirculation and aortic vascular function in the stroke-prone spontaneously hypertensive rat (SHRSP). *Microbial Pathogen*. 2016;92:36–42.
30. Tokutomi F, Wada-Takahashi S, Sugiyama S, Toyama T, Sato T, Hamada N, et al. *Porphyromonas gingivalis*-induced alveolar bone loss is accelerated in the stroke-prone spontaneously hypertensive rat. *Arch Oral Biol*. 2015;60(6):911–8. <https://doi.org/10.1016/j.archoralbio.2015.02.012>.
31. Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. *PLoS Biol*. 2020;18(7):e3000410.
32. Silva LEV, Geraldini VR, de Oliveira BP, Silva CAA, Porta A, Fazan R. Comparison between spectral analysis and symbolic dynamics for heart rate variability analysis in the rat. *Sci Rep*. 2017;7(1):8428. <https://doi.org/10.1038/s41598-017-08888-w>.
33. Silva LEV, Silva CA, Salgado HC, Fazan R. The role of sympathetic and vagal cardiac control on complexity of heart rate dynamics. *Am J Physiol Heart Circ Physiol*. 2017;312(3):H469–77. <https://doi.org/10.1152/ajpheart.00507.2016>.
34. Porta A, Guzzetti S, Montano N, Furlan R, Pagani M, Malliani A, et al. Entropy, entropy rate, and pattern classification as tools to typify complexity in short heart period variability series. *IEEE Trans Biomed Eng*. 2001;48(11):1282–91. <https://doi.org/10.1109/10.959324>.
35. Soriano RN, Kwiatkoski M, Batalhao ME, Branco LG, Carnio EC. Interaction between the carbon monoxide and nitric oxide pathways in the locus coeruleus during fever. *Neuroscience*. 2012;206:69–80. <https://doi.org/10.1016/j.neuroscience.2012.01.021>.
36. Marchesan J, Girmay MS, Jing L, Miao MZ, Zhang S, Sun L, et al. An experimental murine model to study periodontitis. *Nat Protoc*. 2018;13(10):2247–67. <https://doi.org/10.1038/s41596-018-0035-4>.
37. Oz HS, Puleo DA. Animal models for periodontal disease. *J Biomed Biotechnol*. 2011;2011:754857. <https://doi.org/10.1155/2011/754857>.
38. Graves DT, Fine D, Teng YT, Van Dyke TE, Hajishengallis G. The use of rodent models to investigate host-bacteria interactions related to periodontal diseases. *J Clin Periodontol*. 2008;35(2):89–105. <https://doi.org/10.1111/j.1600-051X.2007.01172.x>.
39. Li CH, Amar S. Morphometric, histomorphometric, and microcomputed tomographic analysis of periodontal inflammatory lesions in a murine model. *J Periodontol*. 2007;78(6):1120–8. <https://doi.org/10.1902/jop.2007.060320>.
40. Leite CLA, Redins CA, Vasquez EC, Meyrelles SS. Experimental-induced periodontitis is exacerbated in spontaneously hypertensive rats. *Clin Exp Hypertens*. 2005;27(6):523–31.
41. Górska R, Dembowska E, Konopka TP, Wysokińska-Miszczuk J, Pietruska M, Ganowicz E. Correlation between the state of periodontal tissues and selected risk factors for periodontitis and myocardial infarction. *Adv Clin Exp Med*. 2017;26(3):505–14. <https://doi.org/10.17219/acem/74652>.
42. Leira Y, Seoane J, Blanco M, Rodríguez-Yáñez M, Takkouche B, Blanco J, et al. Association between periodontitis and ischemic stroke: a systematic review and meta-analysis. *Eur J Epidemiol*. 2017;32(1):43–53. <https://doi.org/10.1007/s10654-016-0170-6>.
43. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. *Jpn Circ J*. 1963;27:282–93. <https://doi.org/10.1253/cj.27.282>.
44. Trippodo NC, Frohlich ED. Similarities of genetic (spontaneous) hypertension. *Man Rat Circ Res*. 1981;48(3):309–19. <https://doi.org/10.1161/01.res.48.3.309>.
45. Judy WV, Watanabe AM, Henry DP, Besch HR, Murphy WR, Hockel GM. Sympathetic nerve activity: role in regulation of blood pressure in the spontaneously hypertensive rat. *Circ Res*. 1976;38(6 Suppl 2):21–9. <https://doi.org/10.1161/01.res.38.6.21>.
46. Cabassi A, Vinci S, Calzolari M, Bruschi G, Cavatorta A, Borghetti A. The relationship between regional sympathetic activity and the onset of arterial hypertension in spontaneously hypertensive rats. *Cardiologia*. 1997;42(4):393–6.
47. Miao CY, Xie HH, Zhan LS, Su DF. Blood pressure variability is more important than blood pressure level in determination of end-organ damage in rats. *J Hypertens*. 2006;24(6):1125–35. <https://doi.org/10.1097/01.hjh.0000226203.57818.88>.
48. Silva LEV, Lataro RM, Castania JA, Silva CAA, Salgado HC, Fazan R, et al. Nonlinearities of heart rate variability in animal models of impaired cardiac control: contribution of different time scales. *J Appl Physiol*. (1985). 2017;123(2):344–51. <https://doi.org/10.1152/jappphysiol.00059.2017>.
49. Parwani SR, Parwani RN. Nitric oxide and inflammatory periodontal disease. *Gen Dent*. 2015;63(2):34–40.
50. Vallance P. Nitric oxide. *Biologist (London)*. 2001;48(4):153–8.
51. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. *J Clin Invest*. 1992;90(1):278–81. <https://doi.org/10.1172/JCI115849>.

52. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. *Hypertension*. 1992;20(3):298–303. <https://doi.org/10.1161/01.hyp.20.3.298>.
53. Tonetti MS, D'Aiuto F, Nibali L, Donald A, Storry C, Parkar M, et al. Treatment of periodontitis and endothelial function. *N Engl J Med*. 2007;356(9):911–20. <https://doi.org/10.1056/NEJMoa063186>.
54. Higashi Y, Goto C, Jitsuiki D, Umemura T, Nishioka K, Hidaka T, et al. Periodontal infection is associated with endothelial dysfunction in healthy subjects and hypertensive patients. *Hypertension*. 2008;51(2 PART 2):446–53.
55. Higashi Y, Goto C, Hidaka T, Soga J, Nakamura S, Fujii Y, et al. Oral infection-inflammatory pathway, periodontitis, is a risk factor for endothelial dysfunction in patients with coronary artery disease. *Atherosclerosis*. 2009;206(2):604–10. <https://doi.org/10.1016/j.atherosclerosis.2009.03.037>.
56. Menaka KB, Ramesh A, Thomas B, Kumari NS. Estimation of nitric oxide as an inflammatory marker in periodontitis. *J Indian Soc Periodontol*. 2009;13(2):75–8. <https://doi.org/10.4103/0972-124X.55842>.
57. Sundar NM, Krishnan V, Krishnaraj S, Hemalatha VT, Alam MN. Comparison of the salivary and the serum nitric oxide levels in chronic and aggressive periodontitis: a biochemical study. *J Clin Diagn Res*. 2013;7(6):1223–7. <https://doi.org/10.7860/JCDR/2013/5386.3068>.
58. Batista AC, Silva TA, Chun JH, Lara VS. Nitric oxide synthesis and severity of human periodontal disease. *Oral Dis*. 2002;8(5):254–60. <https://doi.org/10.1034/j.1601-0825.2002.02852.x>.
59. Lohinai Z, Benedek P, Fehér E, Györfi A, Rosivall L, Fazekas A, et al. Protective effects of mercaptoethylguanidine, a selective inhibitor of inducible nitric oxide synthase, in ligature-induced periodontitis in the rat. *Br J Pharmacol*. 1998;123(3):353–60. <https://doi.org/10.1038/sj.bjp.0701604>.
60. Herrera BS, Martins-Porto R, Campi P, Holzhausen M, Teixeira SA, Mendes GD, et al. Local and cardiorenal effects of periodontitis in nitric oxide-deficient hypertensive rats. *Arch Oral Biol*. 2011;56(1):41–7.
61. Angeli F, Verdecchia P, Pellegrino C, Pellegrino RG, Pellegrino G, Prosciutti L, et al. Association between periodontal disease and left ventricle mass in essential hypertension. *Hypertension*. 2003;41(3 I):488–92.
62. Akamatsu Y, Yamamoto T, Yamamoto K, Oseko F, Kanamura N, Imanishi J, et al. Porphyromonas gingivalis induces myocarditis and/or myocardial infarction in mice and IL-17A is involved in pathogenesis of these diseases. *Arch Oral Biol*. 2011;56(11):1290–8. <https://doi.org/10.1016/j.archoralbio.2011.05.012>.
63. DeLeon-Pennell KY, Iyer RP, Ero OK, Cates CA, Flynn ER, Cannon PL, et al. Periodontal-induced chronic inflammation triggers macrophage secretion of Ccl12 to inhibit fibroblast-mediated cardiac wound healing. *JCI Insight*. 2017;2(18). <https://doi.org/10.1172/jci.insight.94207>.
64. Kaneko M, Suzuki JI, Aoyama N, Watanabe R, Yoshida A, Shiheido Y, et al. Toll-like receptor-2 has a critical role in periodontal pathogen-induced myocardial fibrosis in the pressure-overloaded murine hearts. *Hypertens Res*. 2017;40(2):110–6. <https://doi.org/10.1038/hr.2016.117>.
65. Srisuwantha R, Shiheido Y, Aoyama N, Sato H, Kure K, Laosrisin N, et al. Porphyromonas gingivalis elevated high-mobility group box 1 levels after myocardial infarction in mice. *Int Heart J*. 2017;58(5):762–8. <https://doi.org/10.1536/ihj.16-500>.
66. Rothman AM, MacFadyen J, Thuren T, Webb A, Harrison DG, Guzik TJ, et al. Effects of interleukin-1 β inhibition on blood pressure, incident hypertension, and residual inflammatory risk: a secondary analysis of CANTOS. *Hypertension*. 2020;75(2):477–82. <https://doi.org/10.1161/HYPERTENSIONAHA.119.13642>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

